Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients.

Macias J, Gonzalez J, Tural C, Ortega-Gonzalez E, Pulido F, Rubio R, Cifuentes C, Diaz-Menendez M, Jou A, Rubio P, Burgos A, Pineda JA.

AIDS. 2014 Jun 1;28(9):1279-87. doi: 10.1097/QAD.0000000000000248.

OBJECTIVE: To assess the prevalence and factors associated with significant hepatic steatosis (SHS, steatosis involving >/=10% hepatocytes) in HIV-infected patients. DESIGN: A prospective, cross-sectional study. METHODS: Five hundred and five HIV-infected patients were included in this study. All patients underwent a transient elastography examination with the controlled attenuation parameter (CAP). SHS was defined using the previously identified CAP cut-off of 238 dB/m. We analysed the associations between SHS and demographics, metabolic data, coinfections and drug therapy. RESULTS: SHS was detected in 201 (40%) patients. Individuals with and without plasma HIV RNA of 50 copies/ml or less presented SHS in 168 (42%) and 33 (31%) cases, respectively (P = 0.030). Patients with SHS compared with those without SHS presented higher median (IQR) BMI [BMI, 25.6 (22.5-28) vs. 22.3 (20.3-24.2) kg/m; P < 10], DBP [79 (72-85) vs. 74 (68-81) mmHg; P = 0.0001], fasting plasma glucose [95 (87-106) vs. 91 (84-97) mg/dl; P = 0.002] and triglycerides [128 (92-189) vs. 109 (80-167) mg/dl; P = 0.002], and lower HDL cholesterol [44 (37-54) vs. 48 (40-59), mg/dl; P = 0.004]. In multivariate analysis, the only factor associated with SHS was BMI [per unit increase, adjusted odds ratio (95% confidence interval) 1.34 (1.22-1-47); P < 10]. CONCLUSION: SHS measured by CAP is highly prevalent among HIV-infected patients. High BMI is the main predictor of SHS in this setting.

PMID: 24614088

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.